Ocular Therapeutix to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
Ocular Therapeutix announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12-15, 2021.
“We are happy to have a large presence at AAO this year with six poster presentations in five different indications,” said Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The presentations continue to highlight the depth of our pipeline being developed with our novel hydrogel platform. We are excited to be providing data updates on a number of these programs.”
ePosters (On-Demand from Nov 12):
- Efficacy and Safety of an Intracanalicular Dexamethasone Insert (0.4 mg) for the Treatment of Allergic Conjunctivitis. S Silverstein (PO172)
A pooled analysis of randomized, controlled clinical trials assessing efficacy (three Phase 3 clinical trials) and safety (one Phase 2 and three Phase 3 clinical trials) demonstrated DEXTENZA was superior to vehicle insert for treating ocular itching due to allergic conjunctivitis. DEXTENZA had a favorable safety profile and was generally well tolerated with a low rate of adverse events.
- Phase 1/2 Trial Evaluating a Novel, Hydrogel-based Cyclosporine Intracanalicular Insert in Subjects with Dry Eye Disease. W Christie (PO170)
The poster includes a recap of the Phase 1 clinical trial to assess the safety, tolerability, and biological activity of cyclosporine intracanalicular insert (OTX-CSI) in subjects with dry eye disease. The poster also includes the top-line results from the Phase 2 clinical trial, including the data for the primary endpoint of increased tear production at 12 weeks as measured by the Schirmer’s Test; baseline characteristics of the subject population; and retention data showing lower than anticipated insert retention rates in the active drug groups.
- Hydrogel-based, Sustained-release Intracameral Travoprost Implant for Glaucoma Therapy: A Phase 1 Clinical Trial. D. Goldberg (PO212)
Phase 1 clinical trial assessing the safety and biological activity of a single intracameral travoprost implant (OTX-TIC) in glaucoma or ocular hypertension subjects showed a reduction in IOP as least as good as topical travoprost with durations of 6+ months (Cohorts 1&2) and 3-6 months (Cohorts 3&4), consistent hydrogel resorption and a favorable safety profile.
- Phase 1 Trial of a Novel, Hydrogel-based, Intravitreal Axitinib Implant for the Treatment of Neovascular Age-related Macular Degeneration. A Moshfeghi (PO323)
An interim data update of the ongoing Phase 1 Australia-based clinical trial assessing the safety and biological activity of an intravitreal axitinib implant (OTX-TKI) in subjects with wet age-related macular degeneration (wAMD). To date, OTX-TKI has been generally well tolerated and showed preliminary biological signals of durability and meaningful decrease in retinal thickness.
Poster Theatre Presentations
- A Contemporary Retrospective Analysis of Endophthalmitis Following Cataract Surgery Using the IRIS Registry.M Goldstein (PO020, Saturday, Nov 13 3:45 – 3.51 PM)
A retrospective analysis using AAO’s IRIS Registry was used to determine the incidence of and risk factors for endophthalmitis after cataract surgery. The analysis reviewed 6.7 million eyes in 4.1 million patients and identified risk factors for endophthalmitis after cataract surgery from 2016-19 to help identify high risk patients.
- Real-World Evidence of an Intracanalicular Dexamethasone Insert Saving Time on Patient Education and Calls for Post-Cataract Surgery Care. L Nijm (PO021, Saturday, Nov 13 3:55 - 4:01 PM)
Data from a real-world study evaluating the impact of using an intracanalicular dexamethasone insert (DEXTENZA®) on physicians’ practices showed that replacing the complex post-cataract surgery steroid eye drop regimen with physician-administered DEXTENZA saved practices in the study approximately 40 hours each week typically spent on patient education and call backs.
All virtual presentations will be available for those registered starting November 12, 2021, by accessing the American Academy of Ophthalmology’s 2021 Mobile Media Guide. ePosters will be available as of November 12th on the Company’s website (www.ocutx.com, under the Investors tab).